U.S. Logistics Stock News

Interparfums (IPAR) is back in focus after recent data showed institutional investors now hold 66.49% of the company, with largest shareholder Chuck Royce significantly increasing his position last quarter. See our latest analysis for Interparfums. Interparfums’ recent 1 month share price return of 9.77% and 3 month share price return of 10.15%, taking the stock to US$99.09, contrast with a 1 year total shareholder return that declined 22.5%. This suggests improving short term momentum after...

Earlier in 2026, Orkin, a Rollins subsidiary, marked its 125th anniversary by launching the Orkin Insect 2151 Science Fair, a national virtual competition for students aged 14–18 that offers US$180,000 in scholarships to support entomology-focused innovation. This education-focused initiative underscores Rollins’ emphasis on scientific engagement and brand-building in pest control, complementing its recent period of revenue growth and operational improvement. Next, we’ll examine how Orkin’s...

Nio recently reported a sharp turnaround in Q1 2026 with adjusted earnings of ¥0.02 per share, stronger margins, and launched new Champion Edition models with incentives in China while continuing to expand its battery‑swap ecosystem alongside CATL. At the same time, the company is tightening R&D and operating costs through in‑house chip design and restructuring, even as it contests its inclusion on the U.S. “Chinese Military Company List.” Now we’ll examine how Nio’s cost-efficient in-house...

Critical Metals Corp. has commenced its planned 10,000-meter diamond drilling campaign at the wholly owned Tanbreez Rare Earth Project in southern Greenland, following completion of key on-site infrastructure and mobilization of drilling teams. This campaign is a pivotal step in generating the geological and engineering data needed for resource expansion, mine planning, and potential future production of heavy rare earth elements used in electric vehicles, defense systems and advanced...

Pursuit Attractions and Hospitality recently reported past quarterly results showing revenue up 37.42% year over year and net profit rising 19.91%, alongside very high and increasing institutional ownership. This combination of solid financial performance and growing interest from major investors like BlackRock Institutional Trust Company and River Road Asset Management highlights strengthening confidence in the company’s business model despite its low operating efficiency. With...

Earlier this week, Trinity Industries, Inc. entered into a Third Amended and Restated Credit Agreement, securing a US$600.0 million unsecured revolving credit facility maturing as late as June 12, 2031, with leverage-based interest pricing and up to US$100.0 million available for letters of credit. The new facility, which can be expanded by up to US$300.0 million and is currently undrawn, meaningfully reshapes Trinity’s liquidity toolkit and covenant framework by tying pricing and...

Earlier in June 2026, Roche announced an exclusive worldwide licensing and collaboration agreement with Nurix Therapeutics to co-develop and commercialize bexobrutideg (NX-5948), anchored by a US$700 million upfront payment and potential total deal value of up to US$2.30 billion. The agreement pairs Nurix’s BTK degrader platform with Roche’s global development and commercialization infrastructure across oncology, immunology and neurology, potentially reshaping bexobrutideg’s path from a...

Earlier this week, MSC Industrial Direct declared a quarterly cash dividend of US$0.87 per share, payable on July 22, 2026, to shareholders of record on July 8, 2026, with the same date as the ex-dividend date. Alongside this dividend affirmation, recent analyst coverage has turned more constructive on MSC Industrial’s earnings outlook and margin trajectory, reinforcing attention on its cost and productivity initiatives. Against this backdrop, we’ll explore how the combination of an affirmed...

Sabine Royalty Trust (SBR) continues to trade as an income-focused oil and gas royalty vehicle. It is drawing attention after recent price moves and its current intrinsic discount of about 47% relative to estimated value. See our latest analysis for Sabine Royalty Trust. Recent trading has been choppy for Sabine Royalty Trust, with the share price returning 0.65% over the last day but declining 8.13% over 30 days. The 1 year total shareholder return of 16.53% and 5 year total shareholder...

AbbVie (NYSE:ABBV) received U.S. FDA approval for SKINVIVE by JUVÉDERM as the first hyaluronic acid injectable indicated to reduce neck lines. The company reported positive Phase 3 results for a venetoclax based combination therapy in untreated chronic lymphocytic leukemia (CLL) patients. These developments expand AbbVie's aesthetics portfolio and add long term data for its hematology oncology pipeline. For investors watching AbbVie, the latest FDA approval and clinical results highlight...

With the Federal Reserve keeping rates on hold, inflation still elevated, and borrowing costs staying high, the spotlight is back on companies that sell the everyday items households keep buying in good times and bad. This article looks at how that mix of sticky prices, expensive credit, and geopolitical uncertainty around energy could affect large US consumer staples stocks, and why some investors keep returning to this part of the market for potential resilience. Ahead, you will see 3...

With central banks sounding more hawkish, inflation pressures lingering, and energy and wage trends keeping markets on edge, investors are paying closer attention to companies where management is clearly aligned with shareholders. Fast growing stocks with high insider ownership can offer that, as executives have more skin in the game when setting ambitious growth plans and capital allocation decisions. Using the Fast Growing Stocks With High Insider Ownership screener as a starting point,...

Veracyte (VCYT) has drawn attention after recent share price gains over the past month and the past 3 months, prompting a closer look at how its diagnostics business and current valuation might align with investor expectations. See our latest analysis for Veracyte. At a share price of $51.29, Veracyte has seen short term momentum build, with a 30 day share price return of 23.59% feeding into a 1 year total shareholder return of 91.24% and a 3 year total shareholder return of 98.34%. If...

UniQure recently received positive FDA feedback allowing three-year data from its Phase I/II AMT-130 Huntington’s disease study to form the primary basis of a Biologics License Application for potential accelerated approval, while shareholders also approved amendments to its Dutch articles of association, including a higher authorized share capital and an exclusive U.S. federal court forum for certain disputes. This combination of regulatory momentum and corporate governance changes could...

Commerce Bancshares (CBSH) is back in focus after highlighting its performance and outlook at the Morgan Stanley US Financials Conference 2026, following recent revenue and net profit growth, alongside strong operating efficiency metrics. See our latest analysis for Commerce Bancshares. At a share price of $54.73, Commerce Bancshares has seen a 14.79% 90 day share price return and a 5.70% 30 day share price return, while the 1 year total shareholder return has slipped 2.97% and the 3 year...

Recently, Kemper Corp’s institutional shareholding proportion increased very meaningfully quarter-over-quarter to slightly above its share float, giving it the highest institutional ownership score in the US insurance industry. This shift includes an increased position by prominent investor Steven Cohen, signaling heightened professional interest that may influence how other market participants view Kemper’s prospects. We’ll now examine how this surge in institutional ownership, particularly...

Event driven interest around Playtika Holding stock Playtika Holding (PLTK) is drawing fresh attention after announcing a Bingo Blitz collaboration with Where’s Waldo? and a limited time coral reef protection event in Solitaire Grand Harvest, both focused on extending engagement in existing titles. See our latest analysis for Playtika Holding. These content partnerships come as Playtika Holding’s share price shows mixed momentum, with a 12.14% 7 day share price return and a 24.47% 90 day...

Federated Hermes (FHI) has drawn fresh attention after launching the Federated Hermes International Leaders ETF, an actively managed fund targeting developed market stocks that appear undervalued for investors seeking international equity exposure. See our latest analysis for Federated Hermes. Against this backdrop of product launches and new ETF offerings, Federated Hermes shares have climbed, with a 9.96% 1 month share price return and a 12.79% year to date share price return. The 1 year...

US Foods Holding (USFD) recently reported Q1 2026 results, with net sales of $9.6b, 2.8% higher than a year earlier, and total case volume up 1.4%, supported by independent restaurant volume growth. See our latest analysis for US Foods Holding. The Q1 2026 update appears to sit against solid recent momentum, with US Foods Holding’s share price up 13.12% over the past month and a 23.14% year to date share price return. Its 5 year total shareholder return of 137.43% points to strong longer term...

StoneCo (STNE) is drawing fresh attention as investors watch for its upcoming earnings release, with recent upward revisions to earnings estimates and generally positive sentiment shaping expectations ahead of the announcement. See our latest analysis for StoneCo. Despite the current share price of $10.59 and recent excitement around earnings, StoneCo’s 30 day share price return of 2.92% sits against a weaker backdrop. The 90 day share price is down 20.67% and the 1 year total shareholder...

In recent days, Immunovant reported that its FcRn inhibitor Batoclimab achieved clinically meaningful improvements in a Phase IIb trial for chronic inflammatory demyelinating polyneuropathy (CIDP), supporting its potential use in this difficult autoimmune condition. This progress in CIDP adds another possible indication to Immunovant’s FcRn pipeline, deepening its footprint in autoimmune neurology alongside a crowded field of emerging competitors. Next, we’ll examine how Batoclimab’s...

Yum! Brands (YUM) is back in focus after recent share price moves that left the stock roughly flat over the past month and modestly lower over the past 3 months, prompting a closer look at fundamentals. See our latest analysis for Yum! Brands. Over a longer stretch, Yum! Brands has delivered a 1-year total shareholder return of 11.96%, while the share price has been roughly stable in recent months. This may indicate that momentum has cooled following earlier gains. If Yum! Brands has you...

Cytokinetics (CYTK) is back in focus after the FDA cleared its first commercial product, Myqorzo, for symptomatic obstructive hypertrophic cardiomyopathy, with early launch data and European approvals drawing fresh attention to the stock. See our latest analysis for Cytokinetics. Against this backdrop, Cytokinetics' short term share price momentum has been strong, with a 7 day share price return of 13.73% and a 90 day share price return of 27.68%. Its 1 year total shareholder return of...

In recent days, Simpson Manufacturing Co., Inc. released its Fiscal 2025 Corporate Social Responsibility Report and reported quarterly results showing 9.11% year-over-year revenue growth and 13.27% net profit growth, alongside an 11.85% increase in institutional shareholding. The combination of stronger operating performance, higher institutional ownership, and ongoing investments in employee development, product innovation, and environmental initiatives highlights how Simpson is reinforcing...